Peptide conjugated particles for the treatment of allergy
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
1. A method for the treatment of allergy or reduction-of an allergic reaction in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising an allergen encapsulated within a carboxylated poly(lactic-co-glycolic acid) (PLGA) particle with a negative zeta potential between −100 and −30 mV.
2. The method of claim 1 , wherein the zeta potential of the particle is from about −100 mV to about −40 mV.
3. The method of claim 1 , wherein the zeta potential of the particle is from about −50 mV to about −40 mV.
4. The method of claim 1 , wherein the particle has a diameter of between about 0.1 μm to about 10 μm.
5. The method of claim 1 , wherein the particle has a diameter of between about 0.5 μm to about 1 μm.
6. The method of claim 1 , wherein the particle has a diameter of about 0.5 μm.
7. The method of claim 1 , wherein said allergen is an environmental allergen or a food allergen.
8. The method of claim 1 , wherein said allergen comprises all or at least a portion of a protein selected from the group consisting of: ragweed pollen proteins, hair follicle antigen, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Berel Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, and Ovalbumin Egg allergen.
9. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
10. The method of claim 1 , wherein the pharmaceutical composition is administered orally, nasally, intravenously, intramuscularly, ocularly, transdermally, intraperitoneally, or subcutaneously.
11. The method of claim 1 , wherein the pharmaceutical composition is administered intravenously.
12. The method of claim 1 , wherein the PLGA particle further comprises an apoptosis signaling molecule.
13. The method of claim 12 , wherein the apoptosis signaling molecule is attached to the surface of the PLGA particle.
14. The method of claim 13 , wherein the apoptosis signaling molecule is phosphatidyl serine annexin-1, annexin-5, milk fat globule-EGF-factor 8 (MFG-E8) or a thrombospondin.
15. A method for the treatment or prevention of an allergy in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising an allergen encapsulated within a carboxylated poly(lactic-co-glycolic acid) (PLGA) particle with a zeta potential from about −40 mV to about −50 mV and a diameter of about 0.5 μm to about 1.0 μm and a pharmaceutically acceptable carrier.
16. The method of claim 15 , wherein said allergen is an environmental allergen or a food allergen.
17. The method of claim 15 , wherein said allergen comprises all or at least a portion of a protein selected from the group consisting of: ragweed pollen proteins, hair follicle antigen, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Berel Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, and Ovalbumin Egg allergen.
18. The method of claim 15 , wherein the pharmaceutical composition is administered orally, nasally, intravenously, intramuscularly, ocularly, transdermally, intraperitoneally, or subcutaneously.
19. The method of claim 15 , wherein the PLGA particle further comprises an apoptosis signaling molecule conjugated on the particle surface.
20. The method of claim 19 , wherein the apoptosis signaling molecule is phosphatidyl serine annexin-1, annexin-5, milk fat globule-EGF-factor 8 (MFG-E8) or a thrombospondin.
21. The method of claim 1 , wherein the zeta potential of the particle is from about −50 mV to about −30 mV.